# SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

> **NCT04729725** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Anti-TGF-beta Monoclonal Antibody SAR-439459
- **BIOLOGICAL:** Cemiplimab

## Key facts

- **NCT ID:** NCT04729725
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-09
- **Primary completion:** 2022-12-02
- **Final completion:** 2022-12-02
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04729725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04729725, "SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04729725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*